Document is current

Article History

Received: 9 March 2022

Accepted: 22 July 2022

First Online: 8 August 2022

Declarations

:

: The study protocol was reviewed and exempted by the Western Institutional Review Board. Written informed consent was sought from study participants.

: Not applicable.

: A Anagnostou: Principal investigator for Aimmune Therapeutics phase III trials of peanut OIT, Served in Advisory Boards for the SEED trial and DBV Technologies. S. Laubach: Sub-investigator for Aimmune Therapeutics phase II and III trials of peanut OIT, DBV Technologies phase II and III trials of epicutaneous peanut patch. and Alladapt Immunotherapeutics phase II clinical trial of multi-food OIT, with no direct personal financial benefit from any of these trials. A Nowak-Wegrzyn: royalty payments from UpToDate, personal fees from the American College of Allergy, Asthma and Immunology as Deputy Editor of the Annals of Allergy, Asthma, and Immunology, consulting fees from Nestle, Nutricia, Novartis, and Aimmune outside of the submitted work. She serves as the Chair of the Medical advisory Board for the International FPIES Association (uncompensated). S Donelson: employee of Aimmune Therapeutics, Inc. S Tilles: employee of Aimmune Therapeutics, Inc. M Yassine: employee of Aimmune Therapeutics, Inc. Acaster Lloyd Consulting were paid a fixed fee by Aimmune Therapeutics for their role in this research.